10月9日，Vaxcyte盘中上涨5.24%，报68.415美元，成交额2495万美元。此前该公司31价肺炎球菌疫苗VAX-31在三期试验中达所有主要终点，股价大幅走高后出现剧烈波动。
该公司宣布启动普通股、预先融资认股权证及可转换优先票据的公开发行计划，市场担忧股权稀释，短线获利回吐与逢低买盘交替出现。Needham将目标价从110美元上调至122美元，维持买入评级。
Vaxcyte是一家下一代疫苗创新企业，通过无细胞蛋白质合成平台开发预防致命传染病的疫苗，其31价肺炎球菌疫苗VAX-31预计2028年上半年提交FDA生物制品许可申请。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.